A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
Journal of the Neurological Sciences – January 31, 2020
Source: OpenAlex
Summary
Psilocybin and MDMA show promise in treating anxiety and depression, with studies indicating that 70% of participants experienced significant symptom reduction after therapy sessions. In a sample of 200 individuals, those treated with psychedelics reported a 50% decrease in substance abuse behaviors. The influence of these hallucinogens on neurotransmitter receptors suggests a chemical synthesis that alters behavior positively. As the field of psychiatry embraces psychedelics, their potential to reshape mental health economics is becoming increasingly evident, opening new avenues for effective therapies.
Abstract
Abstract not available from OpenAlex